© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Study finds bone health testing for patients with prostate cancer undergoing ADT therapy are not meeting guideline recommendations.
The androgen receptor inhibitor delayed cancer metastasis in a late-stage clinical trial.
The American Society of Clinical Oncology has released new prostate cancer guidelines.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
